Judy S. Wang

1.1k total citations
53 papers, 725 citations indexed

About

Judy S. Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Judy S. Wang has authored 53 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Judy S. Wang's work include Cancer Immunotherapy and Biomarkers (14 papers), Advanced Breast Cancer Therapies (11 papers) and CAR-T cell therapy research (8 papers). Judy S. Wang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Advanced Breast Cancer Therapies (11 papers) and CAR-T cell therapy research (8 papers). Judy S. Wang collaborates with scholars based in United States, United Kingdom and Canada. Judy S. Wang's co-authors include Gerald S. Falchook, Erika Hamilton, Manish R. Patel, Todd M. Bauer, David S. Hong, Kathleen N. Moore, Suzanne F. Jones, Funda Meric‐Bernstam, Susanna V. Ulahannan and Vojislav Vukovic and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Judy S. Wang

49 papers receiving 715 citations

Peers

Countries citing papers authored by Judy S. Wang

Since Specialization

Citations

This map shows the geographic impact of Judy S. Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judy S. Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judy S. Wang more than expected).

Fields of papers citing papers by Judy S. Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judy S. Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judy S. Wang. The network helps show where Judy S. Wang may publish in the future.

Co-authorship network of co-authors of Judy S. Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Judy S. Wang. A scholar is included among the top collaborators of Judy S. Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judy S. Wang. Judy S. Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors 2025 ·Investigational New Drugs ·Judy S. Wang, Edward Arrowsmith, J. Thaddeus Beck, Jennifer Friedmann, Rahima Jamal, (unknown), Humphrey Gardner, Michael Chisamore, Susanna V. Ulahannan	1
2	Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4-directed dolasynthen antibody-drug conjugate. 2025 ·Journal of Clinical Oncology ·Erika Hamilton, Hyo S. Han, Kevin Kalinsky, Nour Abuhadra, Nicholas P. McAndrew, Alexander I. Spira, (unknown), David Starks, Gerburg M. Wulf, Arvind Chaudhry, (unknown), Ritesh Parajuli, Judy S. Wang, Joyce O’Shaughnessy, Amy Weise, Debra L. Richardson, Dario R. Roque, Renata Ferrarotto, Nora Zizlsperger, (unknown)	1
3	CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial 2024 ·Investigational New Drugs ·Andrew J. Armstrong, Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H. Miller, Aaron R. Hansen, Jong Seok Lee, Frank Tsai, Benjamin Solomon, Tae Min Kim, Christian Rolfo, Vincent L. Giranda, Yixin Ren, Fang Liu, (unknown), Tomoko Freshwater, Judy S. Wang	33
4	Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation. 2024 ·Journal of Clinical Oncology ·Judy S. Wang, David Sommerhalder, Manish Sharma, William J. Edenfield, Kartik Sehgal, Do‐Youn Oh, Yixing Jiang, Joel Michalski, Jeeyun Lee, Hans J. Hammers, Li‐Yuan Bai, Chih‐Hung Hsu, (unknown), Kefei Zhou, Lisa K. Blum, (unknown), (unknown), Hsiao D. Lieu, Vladimir Hanes, Aung Naing	2
5	Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study. 2024 ·Journal of Clinical Oncology ·Ignacio Melero, Judy S. Wang, Martin Gutierrez, Erika Hamilton, Alexander I. Spira, Drew Rasco, John D. Powderly, Michael Millward, Sophia Frentzas, Rafał Stec, Manish Sharma, Mark Shackleton, Ana Arance, (unknown), Iwona Ługowska, Tracy Liu, Todd Shearer, Divya Gupta, Jeffrey A. Jones, Víctor Moreno	1
6	Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial 2024 ·Targeted Oncology ·Erika Hamilton, Gerald S. Falchook, Judy S. Wang, Siqing Fu, Amit M. Oza, (unknown), Sanjeev Kumar, Lone H. Ottesen, Ganesh Mugundu, Elza C. de Bruin, Mark J. O’Connor, Suzanne F. Jones, David R. Spigel, Bob T. Li	3
7	H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC). 2024 ·Journal of Clinical Oncology ·Erika Hamilton, Timothy Pluard, Judy S. Wang, Aki Morikawa, Stephen Johnston, Elizabeth Claire Dees, Christos Vaklavas, Anne Armstrong, Pamela N. Münster, Nisha Unni, (unknown), Fadi Kayali, Tingting Song, (unknown), (unknown), Dejan Juric	4
8	First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors 2024 ·Molecular Cancer Therapeutics ·Melissa L. Johnson, Beni B. Wolf, Judy S. Wang, Alexander Philipovskiy, Geoffrey I. Shapiro, Bruno Bockorny, (unknown), (unknown), (unknown), (unknown), (unknown), Mahesh V. Padval, Oleg Schmidt‐Kittler, (unknown), Sarita Dubey, Julia Suchomel, Johanna C. Bendell, (unknown), Jennifer Eng‐Wong, W. Marston Linehan	0
9	H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC). 2024 ·Journal of Clinical Oncology ·Stephen Johnston, Timothy Pluard, Judy S. Wang, Erika Hamilton, Tingting Song, (unknown), (unknown), Dejan Juric	4
10	First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma 2023 ·Molecular Cancer Therapeutics ·Erika Hamilton, Judy S. Wang, Amit M. Oza, Manish R. Patel, Susanna V. Ulahannan, Todd M. Bauer, Janet L. Karlix, Jorge Zerón-Medina, (unknown), Paola Marco‐Casanova, Ganesh Moorthy, Maureen M. Hattersley, (unknown), Pat Mitchell, Jamal Saeh, Gayle P. Pouliot, Kathleen N. Moore	14
11	Abstract 921: Identification of NRG1 fusions in patients with solid tumors: analysis from a real-world community oncology network 2023 ·Cancer Research ·(unknown), (unknown), (unknown), (unknown), Daniel J. Luckett, Cesar A. Perez, Judy S. Wang, Stephen G. Divers, Babar Bashir, Jennifer M. Johnson, Valerie M. Jansen, Andrew J. McKenzie, David R. Spigel	1
12	Clinical and molecular presentation of KRAS G12D-mutated pancreatic ductal adenocarcinoma in real-world settings. 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Daniel J. Luckett, (unknown), Marilyn Holt, (unknown), Suzanne F. Jones, Cesar A. Perez, Judy S. Wang, Stephen G. Divers, Meredith Pelster, Jason T. Henry, David R. Spigel, Howard A. Burris, Andrew J. McKenzie	1
13	Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor 2021 ·Clinical Cancer Research ·David S. Hong, Kathleen N. Moore, Johanna C. Bendell, Daniel D. Karp, Judy S. Wang, Susanna V. Ulahannan, Suzanne F. Jones, Wenjuan Wu, Gregory P. Donoho, Yan Ding, Andrew Capen, (unknown), Aimee Bence Lin, Manish R. Patel	37
14	Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide 2021 ·Clinical Cancer Research ·Johann S. de Bono, Mark T. Fleming, Judy S. Wang, Richard Cathomas, (unknown), John Bothos, Mary Jane Hinrichs, Qu Zhang, Peng He, Marna Williams, Anton I. Rosenbaum, Meina Liang, (unknown), Song Cho, Pablo Martínez, Daniel P. Petrylak	33
15	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 2021 ·Clinical Cancer Research ·Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric‐Bernstam	110
16	A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors 2021 ·Investigational New Drugs ·Gerald S. Falchook, Marc Peeters, Sylvie Rottey, Luc Dirix, Radka Obermannová, Jonathan Cohen, Ruth Perets, Ronnie Shapira Frommer, Todd M. Bauer, Judy S. Wang, Richard D. Carvajal, Joshua K. Sabari, Sonya C. Chapman, Wei Zhang, Boris Calderón, Daniel A. Peterson	47
17	A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer 2021 ·Targeted Oncology ·Kathleen N. Moore, David S. Hong, Manish R. Patel, Shubham Pant, Susanna V. Ulahannan, Suzanne F. Jones, Funda Meric‐Bernstam, Judy S. Wang, Raid Aljumaily, Erika Hamilton, Erika S. Wittchen, Xuejing Wang, Aimee Bence Lin, Johanna C. Bendell	20
18	Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors 2020 ·Cancer Immunology Immunotherapy ·Kyriakos P. Papadopoulos, Nehal J. Lakhani, Gerald S. Falchook, (unknown), Johan Baeck, Karen Brown, (unknown), (unknown), Judy S. Wang	5
19	Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity 2019 ·Clinical Cancer Research ·Devalingam Mahalingam, Judy S. Wang, Erika Hamilton, John Sarantopoulos, John Nemunaitis, (unknown), Laura Carter, Xiao Hu, Marshall T. Schreeder, H. Jeffrey Wilkins	47
20	Histone modifications in Rett syndrome lymphocytes: a preliminary evaluation 2004 ·Brain and Development ·Walter E. Kaufmann, Mohammed Jarrar, Judy S. Wang, (unknown), (unknown), Genila Bibat, Sakkubai Naidu	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact